Merus N.V. (NASDAQ:MRUS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company’s bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. “

A number of other research firms also recently issued reports on MRUS. ValuEngine downgraded Merus N.V. from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $31.00 price target on shares of Merus N.V. in a research note on Friday, July 14th. Finally, Royal Bank Of Canada assumed coverage on Merus N.V. in a research note on Thursday, September 14th. They set an “outperform” rating and a $28.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $30.50.

Shares of Merus N.V. (NASDAQ:MRUS) opened at 20.70 on Wednesday. The company’s market cap is $401.50 million. The company’s 50-day moving average price is $18.26 and its 200 day moving average price is $18.26. Merus N.V. has a 12-month low of $13.13 and a 12-month high of $29.75.

ILLEGAL ACTIVITY WARNING: “Merus N.V. (MRUS) Downgraded to “Sell” at Zacks Investment Research” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/11/merus-n-v-mrus-downgraded-to-sell-at-zacks-investment-research.html.

A number of hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP acquired a new position in Merus N.V. during the 1st quarter valued at about $29,841,000. Iguana Healthcare Management LLC boosted its stake in Merus N.V. by 16.7% during the 1st quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock valued at $4,268,000 after purchasing an additional 25,000 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Merus N.V. during the 1st quarter valued at about $976,000. Renaissance Technologies LLC acquired a new position in Merus N.V. during the 1st quarter valued at about $549,000. Finally, Spark Investment Management LLC acquired a new position in Merus N.V. during the 1st quarter valued at about $458,000. Institutional investors and hedge funds own 32.16% of the company’s stock.

Merus N.V. Company Profile

Get a free copy of the Zacks research report on Merus N.V. (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related companies with MarketBeat.com's FREE daily email newsletter.